Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

In vitro efficacy of artemisinin-based treatments against SARS-CoV-2

Research output: Contribution to journalJournal articlepeer-review

  1. Exercise suppresses tumor growth independent of high fat food intake and associated immune dysfunction

    Research output: Contribution to journalJournal articlepeer-review

  2. Initial evidence of abnormal brain plasticity in anorexia nervosa: an ultra-high field study

    Research output: Contribution to journalJournal articlepeer-review

  3. Systematically evaluating DOTATATE and FDG as PET immuno-imaging tracers of cardiovascular inflammation

    Research output: Contribution to journalJournal articlepeer-review

  4. Time to CT scan for patients with acute severe neurological symptoms: a quality assurance study

    Research output: Contribution to journalJournal articlepeer-review

  1. High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor

    Research output: Contribution to journalJournal articlepeer-review

  2. Neutralizing Antibodies Against Hepatitis C Virus and Their Role in Vaccine Immunity

    Research output: Contribution to journalEditorialpeer-review

View graph of relations

Effective and affordable treatments for patients suffering from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are needed. We report in vitro efficacy of Artemisia annua extracts as well as artemisinin, artesunate, and artemether against SARS-CoV-2. The latter two are approved active pharmaceutical ingredients of anti-malarial drugs. Concentration-response antiviral treatment assays, based on immunostaining of SARS-CoV-2 spike glycoprotein, revealed that treatment with all studied extracts and compounds inhibited SARS-CoV-2 infection of VeroE6 cells, human hepatoma Huh7.5 cells and human lung cancer A549-hACE2 cells, without obvious influence of the cell type on antiviral efficacy. In treatment assays, artesunate proved most potent (range of 50% effective concentrations (EC50) in different cell types: 7-12 µg/mL), followed by artemether (53-98 µg/mL), A. annua extracts (83-260 µg/mL) and artemisinin (151 to at least 208 µg/mL). The selectivity indices (SI), calculated based on treatment and cell viability assays, were mostly below 10 (range 2 to 54), suggesting a small therapeutic window. Time-of-addition experiments in A549-hACE2 cells revealed that artesunate targeted SARS-CoV-2 at the post-entry level. Peak plasma concentrations of artesunate exceeding EC50 values can be achieved. Clinical studies are required to further evaluate the utility of these compounds as COVID-19 treatment.

Original languageEnglish
Article number14571
JournalScientific Reports
Volume11
Issue number1
Pages (from-to)1-14
Number of pages14
ISSN2045-2322
DOIs
Publication statusPublished - 16 Jul 2021

    Research areas

  • A549 Cells, Animals, Artemisia annua/chemistry, Artemisinins/pharmacology, COVID-19/drug therapy, Chlorocebus aethiops, Humans, Plant Extracts/pharmacology, SARS-CoV-2/drug effects, Vero Cells

ID: 66727254